9,190 Shares in Merit Medical Systems, Inc. (NASDAQ:MMSI) Purchased by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC acquired a new position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 9,190 shares of the medical instruments supplier's stock, valued at approximately $889,000.

Several other large investors have also made changes to their positions in the company. Louisiana State Employees Retirement System raised its holdings in shares of Merit Medical Systems by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,200 shares of the medical instruments supplier's stock worth $2,728,000 after purchasing an additional 100 shares during the period. Avantax Advisory Services Inc. raised its holdings in Merit Medical Systems by 4.6% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,347 shares of the medical instruments supplier's stock valued at $227,000 after buying an additional 103 shares during the period. Tidal Investments LLC lifted its position in Merit Medical Systems by 1.0% during the third quarter. Tidal Investments LLC now owns 10,398 shares of the medical instruments supplier's stock valued at $1,028,000 after buying an additional 104 shares in the last quarter. Arizona State Retirement System increased its position in shares of Merit Medical Systems by 0.8% in the fourth quarter. Arizona State Retirement System now owns 16,869 shares of the medical instruments supplier's stock worth $1,632,000 after acquiring an additional 137 shares in the last quarter. Finally, Summit Investment Advisors Inc. increased its position in shares of Merit Medical Systems by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,987 shares of the medical instruments supplier's stock worth $579,000 after acquiring an additional 190 shares in the last quarter. 99.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MMSI has been the subject of a number of research reports. Canaccord Genuity Group decreased their price target on shares of Merit Medical Systems from $127.00 to $108.00 and set a "buy" rating for the company in a research report on Friday, April 25th. Robert W. Baird dropped their target price on Merit Medical Systems from $111.00 to $110.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Barrington Research reduced their price target on Merit Medical Systems from $111.00 to $103.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Wells Fargo & Company set a $106.00 price objective on shares of Merit Medical Systems and gave the company an "overweight" rating in a research note on Friday, April 25th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Merit Medical Systems in a research note on Friday, March 28th. They issued an "overweight" rating and a $120.00 target price for the company. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $107.78.

Merit Medical Systems Stock Down 1.1 %

Shares of MMSI stock traded down $1.08 during trading hours on Tuesday, hitting $92.87. 646,975 shares of the company were exchanged, compared to its average volume of 503,047. The stock has a market capitalization of $5.49 billion, a price-to-earnings ratio of 45.52, a P/E/G ratio of 2.34 and a beta of 0.70. Merit Medical Systems, Inc. has a one year low of $78.73 and a one year high of $111.45. The business's 50-day simple moving average is $97.53 and its two-hundred day simple moving average is $100.56. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last released its earnings results on Thursday, April 24th. The medical instruments supplier reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.11. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The company had revenue of $355.35 million for the quarter, compared to the consensus estimate of $352.57 million. During the same quarter last year, the business posted $0.77 EPS. Merit Medical Systems's quarterly revenue was up 9.8% compared to the same quarter last year. Sell-side analysts predict that Merit Medical Systems, Inc. will post 3.37 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Raul Jr. Parra sold 12,451 shares of the stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $98.81, for a total transaction of $1,230,283.31. Following the sale, the chief financial officer now owns 24,201 shares in the company, valued at $2,391,300.81. This represents a 33.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Fred P. Lampropoulos sold 31,320 shares of Merit Medical Systems stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $103.86, for a total value of $3,252,895.20. Following the completion of the transaction, the chief executive officer now owns 1,086,028 shares of the company's stock, valued at approximately $112,794,868.08. The trade was a 2.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 109,132 shares of company stock worth $11,139,521 over the last ninety days. 3.20% of the stock is owned by insiders.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.